Cannabis Bioscience International Holdings, Inc. financial statements
Income statement, balance sheet and cash flow statement for the last 3 fiscal years, taken from the XBRL data Cannabis Bioscience International Holdings, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
Revenue
0.32
0.25
0.3
Cost of revenue
0.09
0.05
0.04
Gross profit
0.22
0.2
0.26
General and administrative
0.18
0.12
0.1
Operating expenses
1.21
0.69
0.68
Operating income
-0.98
-0.49
-0.42
Interest expense
0.09
0.15
0.14
Other non-operating income
-0.05
-0.17
-0.13
Income tax
0
0
Net income
-1.03
-0.65
-0.55
EPS, basic
-0.00
-0.00
-0.00
EPS, diluted
-0.00
-0.00
-0.00
Shares, basic (weighted)
9,002
10,318
10,716
Shares, diluted (weighted)
9,002
10,318
10,716
Balance sheet
FY2024
FY2024
FY2025
Cash and equivalents
0.01
0
0.01
Receivables
0.01
0.02
0.01
Other current assets
0
0
0
Total current assets
0.02
0.02
0.03
Lease right-of-use assets
0.02
0.04
0
Total assets
0.04
0.06
0.03
Accounts payable
0.11
0.17
0.1
Deferred revenue
0.03
0
Short-term debt
0.01
0.01
0.01
Total current liabilities
0.39
0.88
0.95
Long-term debt
0.25
0.25
0.25
Lease liabilities
0
0
0
Total liabilities
0.64
1.14
1.2
Total debt
0.26
0.26
0.29
Paid-in capital
4.09
4.26
4.72
Retained earnings
-4.68
-5.33
-5.88
Shareholders' equity
-0.59
-1.08
-1.16
Total equity
-0.59
-1.08
-1.16
Total liabilities and equity
0.04
0.06
0.03
Shares outstanding
10,060
10,432
11,627
Cash flow statement
FY2024
FY2024
FY2025
Net income
-1.03
-0.65
-0.55
Stock-based compensation
0.01
0
Change in receivables
-0
-0.01
0.01
Change in payables
0.04
0.08
-0.07
Cash from operations
-0.9
-0.48
-0.33
Cash from financing
0.88
0.47
0.34
Net change in cash
-0.02
-0.01
0.01
Interest paid
0.09
0.09
0.14
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to February 28, 2026; growth uses fiscal years. Valuation uses the share price of $0.00 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
78.8%
Gross profit / revenue.
Operating margin
-322.6%
Operating income / revenue.
Net margin
-416.8%
Net income / revenue.
Operating cash flow margin
-216.9%
Cash from operations / revenue.
Return on assets (ROA)
-33,374.0%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
21.8%
Revenue vs the same period a year earlier. Only from a positive base.
Gross profit growth, 1y
29.4%
Gross profit vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
-44.2%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
3.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.00x
Current assets / current liabilities.
Quick ratio
0.00x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.00x
(Cash + short-term investments) / current liabilities.
Debt / assets
18,838.0%
Total debt / total assets.
Liabilities / assets
95,121.0%
Total liabilities / total assets.
Net debt
$290.8K
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.00
Cash from operations / diluted weighted shares.
Book value per share
-$0.00
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
9.40x
Market cap / revenue.
EV/Sales
11.8x
Enterprise value / revenue.
Earnings yield
-44.3%
Net income / market cap (the inverse of P/E).
What was Cannabis Bioscience International Holdings, Inc.'s revenue in fiscal 2025?
Cannabis Bioscience International Holdings, Inc. reported revenue of $303.0K for fiscal 2025, 21.8% higher than the year before.
Was Cannabis Bioscience International Holdings, Inc. profitable in fiscal 2025?
No. It reported a net loss of $548.8K.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.